Nuvo Research announces director election results of its annual general meeting
June 11 2014 - 3:30PM
PR Newswire (Canada)
MISSISSAUGA, ON, June 11, 2014 /CNW/ - Nuvo Research Inc.
(TSX: NRI) a specialty pharmaceutical company with a diverse
portfolio of topical and immunology products today announced that
at its 2014 Annual and Special Meeting of Shareholders held in
Toronto, all nominees listed in
the management proxy circular dated April
30, 2014 were elected as directors of the Company.
The detailed results of the votes by proxy are as follows:
Director
Nominees
|
NUMBER OF
SHARES
|
PERCENTAGE OF VOTES
CAST
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
Daniel
Chicoine
|
3,280,929
|
196,987
|
94.34
|
5.66
|
David A.
Copeland
|
3,279,013
|
198,903
|
94.28
|
5.72
|
Anthony E.
Dobranowski
|
3,279,784
|
198,132
|
94.30
|
5.70
|
Dr. Henrich R.K.
Guntermann
|
3,345,441
|
132,475
|
96.19
|
3.81
|
Dr. Klaus von
Lindeiner
|
3,280,884
|
197,032
|
94.33
|
5.67
|
John C.
London
|
3,280,958
|
196,958
|
94.34
|
5.66
|
Dr. Jacques
Messier
|
3,280,127
|
197,789
|
94.31
|
5.69
|
Dr. Theodore H.
Stanley
|
3,285,630
|
192,286
|
94.47
|
5.53
|
About Nuvo Research Inc.
Nuvo (TSX:NRI) is a
specialty pharmaceutical company with a diverse portfolio of
products and technologies. The Company operates two distinct
business units: the Topical Products and Technology (TPT) Group and
the Immunology Group. The TPT Group has four U.S. Food and
Drug Administration (FDA) approved commercial products, a pipeline
of topical and transdermal products focusing on pain and
dermatology and four drug delivery platforms that support the
creation of patented formulations that can deliver actives into or
through the skin. The Immunology Group has two commercial
products, a development program for the treatment of allergic
rhinitis and an immune system modulation platform that has the
potential to support treatments for a broad range of immune system
related disorders. For additional company information
visit www.nuvoresearch.com.
SOURCE Nuvo Research Inc.
Copyright 2014 Canada NewsWire